Anti-B16 melanoma effects of a STAT3 inhibitor (rR9-GRIM19) are strongly enhanced by co-treatment with recombinant interferons. Issue 1 (October 2016) - Okamoto, Takashi; Shibagaki, Naotaka; Shimada, Shinji